Global Fabry Disease Market 2026 expected to reach $3.27 billion by 2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Fabry Disease Market By The End Of 2030?

The fabry disease market has demonstrated robust expansion in recent years. It is anticipated to expand from $2.26 billion in 2025 to $2.43 billion in 2026, at a compound annual growth rate (CAGR) of 7.7%. The market’s historical growth can be attributed to heightened awareness of rare genetic disorders, the approval of enzyme replacement therapies, the expansion of specialty clinics, the proliferation of genetic screening programs, and escalating diagnosis rates.

The market size for Fabry disease is anticipated to show significant expansion in the coming years. It is projected to achieve $3.27 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.7%. This forecasted growth can be attributed to advancements in gene-based treatments, the broadening of newborn screening programs, increasing healthcare expenditure on rare diseases, the expansion of personalized medicine, and the development of next-generation oral therapies. Noteworthy trends during the forecast period include the increasing adoption of enzyme replacement therapy, a heightened focus on rare disease diagnosis, the growing application of genetic testing for early detection, the expansion of oral and adjunct therapies, and the increasing implementation of patient-centric treatment approaches.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24218&type=smp

Which Market Drivers Are Supporting The Expansion Of The Fabry Disease Market?

A rising emphasis on personalized medicine is anticipated to stimulate the expansion of the fabry disease market. This therapeutic method leverages an individual’s genetic, environmental, and lifestyle data to customize medical interventions and therapies for superior results. The increasing focus on personalized medicine is fueled by its potential to enhance treatment efficacy and mitigate adverse reactions through therapies adapted to individual patient requirements. It facilitates the customization of treatment regimens according to a patient’s distinct genetic mutation and disease severity, thereby optimizing results and curbing superfluous side effects. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA granted approval for 16 new personalized treatments for rare disease patients, a notable rise from the six approvals in 2022. Consequently, the heightened focus on personalized medicine is a pivotal factor propelling the expansion of the fabry disease market.

Which Segment Classifications Shape The Fabry Disease Market?

The fabry disease market covered in this report is segmented –

1) By Type: Type 1, Type 2, Other Types

2) By Treatment: Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Other Treatments

3) By Diagnosis: Blood Test, Genetic Test, Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Type 1: Classic Fabry Disease, Later-Onset Fabry Disease

2) By Type 2: Cardiovascular-Focused Fabry Disease, Renal-Focused Fabry Disease

3) By Other Types: Variant Fabry Disease, X-linked Fabry Disease

How Are Trends Impacting The Fabry Disease Market?

Leading companies in the Fabry disease market are concentrating on developing innovative treatments, such as PEGylated enzyme replacement therapy (ERT), to improve treatment efficacy, enhance patient compliance, and reduce immunogenic reactions linked to conventional ERTs. PEGylated enzyme replacement therapy (ERT) is a modified version of traditional ERT where polyethylene glycol (PEG) chains are attached to the enzyme to boost its stability, extend its circulation time in the body, and decrease immune system responses. For instance, in May 2023, Chiesi Global Rare Diseases, a division of the Italy-based pharmaceutical company Chiesi Group, announced the U.S. Food and Drug Administration (FDA), a US-based government agency, had approved PRX-102 (pegunigalsidase alfa) for the treatment of adult Fabry disease patients. This approval is underpinned by a robust clinical program involving over 140 patients and long-term follow-up of up to 7.5 years, which demonstrated the therapy’s effectiveness in reducing renal Gb₃ deposits and preserving kidney function while showing a favorable safety profile.

Which Companies Are Expanding Their Footprint In The Fabry Disease Market?

Major companies operating in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH

Read the full fabry disease market report here:

https://www.thebusinessresearchcompany.com/report/fabry-disease-global-market-report

How Is The Fabry Disease Market Distributed Across Key Geographic Regions?

North America was the largest region in the fabry disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Fabry Disease Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24218&type=smp

Browse Through More Reports Similar to the Global Fabry Disease Market 2026, By The Business Research Company

Fabry Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/fabry-disease-treatment-global-market-report

Gauchers Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/gauchers-disease-global-market-report

Carcinoembryonic Antigen Market Report 2026

https://www.thebusinessresearchcompany.com/report/carcinoembryonic-antigen-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795